Drugs Made In America Acquisition Corp. (DMAAR) Liabilities and Shareholders Equity (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $146.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 37.54% year-over-year to $146.9 million; the trailing twelve-month figure through Jun 2026 stood at $859.7 million (changed N/A YoY), and the FY2025 full-year result was $239.9 million, up 43456.35% from the prior year.
• Liabilities and Shareholders Equity declined to $146.9 million in Q2 2026 per DMAAR's latest filing, from $239.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $239.9 million in Q4 2025 and bottomed at $550824.0 in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $182.2 million across 3 years, with a median of $234.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity surged 43456.35% in 2025, then sank 37.54% in 2026.
• Over 3 years, Liabilities and Shareholders Equity stood at $550824.0 in 2024, then soared by 43456.35% to $239.9 million in 2025, then sank by 38.77% to $146.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $146.9 million, $239.9 million, and $237.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.